Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Bruce E SandsWilliam J SandbornRemo PanaccioneChristopher D O'BrienHongyan ZhangJewel JohannsOmoniyi J AdedokunKatherine LiLaurent Peyrin-BirouletGert Van AsscheSilvio DaneseStephan TarganMaria T AbreuTadakazu HisamatsuPhilippe SzaparyColleen Maranonull null

Published in: The New England journal of medicine (2019)

Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. (Funded by Janssen Research and Development; UNIFI ClinicalTrials.gov number, NCT02407236.).

Keyphrases

ulcerative colitis
high intensity
early onset
double blind
randomized controlled trial
clinical trial
rheumatoid arthritis
disease activity